<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2946515/" ref="ordinalpos=3367&amp;ncbi_uid=3257686&amp;link_uid=PMC2946515" image-link="/pmc/articles/PMC2946515/figure/F3/" class="imagepopup">Figure 3.  From: Epidermal Growth Factor Receptor Targeted Therapy of Squamous Cell Carcinoma of the Head and Neck. </a></div><br /><div class="p4l_captionBody">The mutant epidermal growth factor receptor, EGFRvIII, promotes cell survival and proliferation by preferential signaling through the phosphotidyinositol-3-kinase (PI3K) pathway. The wild-type receptor utilizes both the PI3K pathway and the Ras-Raf-MEK pathway. Downstream effectors of both pathways further promote cell survival via inhibition of apoptosis.</div></div>